Skip to content

Inogen INGN Concentration Risk %

Discontinued — last reported Q2 '16

Concentration Risk % at other companies

Identive logo
IdentiveINVE
10.3%+7.7pp
Heartland Express logo
Heartland ExpressHTLD
32%+6.0pp
Enovix Corporation logo
Enovix CorporationENVX
83%+36.0pp
RF Industries logo
RF IndustriesRFIL
100%0.0pp
Weis Markets logo
Weis MarketsWMK
100%0.0pp
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
93.1%-5.3pp

Segments

By product

See full
Medicares Service Reimbursement Programs62.6%+13.8%

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-7.6%
Enterprise value$98.45M-5.8%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.

The official record: Inogen’s 10-Q, filed August 4, 2016, on SEC EDGAR. View the filing →